You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Dynamic Frequency Passive Millimeter-Wave Radiometer Based on Optical Up-Conversion

    SBC: PHASE SENSITIVE INNOVATIONS INC            Topic: 941D

    In the proposed effort, we will leverage this extensive experience and capabilities to realize a frequency agile mmW radiometer that can cover the range of DC-110 GHz and can be scaled to DC-200 GHz under Phase II. Ours is a photonic system that multiplies and up-coverts a low-frequency reference signal onto an optical carrier (laser) using EO modulation, then uses the modulation sidebands to inj ...

    SBIR Phase I 2013 Department of CommerceNational Oceanic and Atmospheric Administration
  2. Development of a Long Term pH and pCO2 Lagrangian Drifter

    SBC: SUNBURST SENSORS, LLC            Topic: 831C

    Quantifying oceanic CO2 uptake and ocean acidification and understanding their impact on global climate and ocean ecology are key goals of NOAA’s climate change research programs. NOAA’s request for Development of a long-term Lagrangian pH and pCO2 drifter (SBIR Subtopic 8.3.1C) aims to address these goals by developing technology that measures both pCO2 and pH that can be widely deployed in t ...

    SBIR Phase II 2013 Department of CommerceNational Oceanic and Atmospheric Administration
  3. Inhibition of retinoic acid metabolism for reversal of cognitive deficits in AD

    SBC: DERMAXON LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a progressive and ultimately fatal neurodegenerative disease that affects more than five million people in the USA. Currently there is no cure for AD. Available medicines are aimed only at temporarily reducing symptoms and slowing down the progression of the disease. While many new compounds have been developed to treat AD, they ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A Synthetic Human Cytomegalovirus Vaccine Platform

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Antimicrobial-releasing gels for preventing infection in total joint arthroplasty

    SBC: SONORAN BIOSCIENCES INC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Orthopaedic Surgical Site Infections (SSIs), including Prosthetic Joint Infections (PJIs), are an extremely costly health care problem, illustrated by the 70,000- 114,000 average total cost per case to treat more than20,000 hip and knee replacement infections in the US each year. When a prosthetic joint becomes infected following arthroplasty, organisms form ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Decoy Peptides: Development of a Novel Therapeutic for Metastatic Cancer

    SBC: ARIZONA CANCER THERAPEUTICS L.L.C.            Topic: NCI

    DESCRIPTION (provided by applicant): Arizona Cancer Therapeutics LLC (ACT) proposes a two-year, preclinical research project in cooperation with the University of Arizona Cancer Center to develop the novel anti-tumor therapeutic, Protein transduction domain-MUC1 Inhibitory Peptide (PMIP). PMIP is an intracellular MUC1 peptide that acts as a decoy to block the MUC1- oncoprotein interactions that dr ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Slip-flow chromatography

    SBC: BIOVIDRIA, INC.            Topic: NIGMS

    DESCRIPTION: The product will be a packed capillary for nanoUHPLC of peptides that provides a dramatic increase in speed and efficiency. Current commercial columns for high speed and efficiency use sub-2 mm particles. The proposed technology uses sub-0.2mm particles. The ability to use such small particles for UHPLC is enabled by the phenomenon of slip flow, which gives enhanced volume flow rat ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Biopsy and Freezing of Later-stage Mouse Blastocysts Using the Dracula Pipette

    SBC: GENESEARCH, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Procedures on pre-implantation embryos are a cornerstone of much biomedical research; however in all cases, the procedures are very difficult and delicate, requiring exceptionally skilled technical experts and expensive equipment. The difficulties associated with these procedures often results in most such work being avoided by most biomedical research groups. ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Reduced gluten cereal grains

    SBC: Arcadia Biosciences, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Celiac disease (CD) is the most common food sensitive enteropathy known, affecting approximately 1% of the population and its incidence appears to be on the rise. In addition, non-celiac gluten sensitivity (GS) has recently been revealed to be a distinct condition that affects a growing number of individuals. Both of these conditions are triggered by gluten, a ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)

    SBC: IRON HORSE DIAGNOSTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) is a fatal neurodegenerative disease with a typical lifespan of 3 - 5 years after diagnosis. The initial symptoms can be similar to many other neurologic disorders and often begin with limb weakness, muscle fasciculations, or increasing difficulties in speech or breathing. No definitive diagnostic ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government